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Zika virus (ZIKV) remained largely quiescent for nearly six decades after its first
appearance in 1947. ZIKV reappeared after 2007, resulting in a declaration of an
international “public health emergency” in 2016 by the World Health Organization
(WHO). Until this time, ZIKV was considered to induce only mild illness, but it
has now been established as the cause of severe clinical manifestations, including
fetal anomalies, neurological problems, and autoimmune disorders. Infection during
pregnancy can cause congenital brain abnormalities, including microcephaly and
neurological degeneration, and in other cases, Guillain-Barré syndrome, making
infections with ZIKV a substantial public health concern. Genomic and molecular
investigations are underway to investigate ZIKV pathology and its recent enhanced
pathogenicity, as well as to design safe and potent vaccines, drugs, and therapeutics.
This review describes progress in the design and development of various anti-
ZIKV therapeutics, including drugs targeting virus entry into cells and the helicase
protein, nucleosides, inhibitors of NS3 protein, small molecules, methyltransferase
inhibitors, interferons, repurposed drugs, drugs designed with the aid of computers,
neutralizing antibodies, convalescent serum, antibodies that limit antibody-dependent
enhancement, and herbal medicines. Additionally, covalent inhibitors of viral protein
expression and anti-Toll-like receptor molecules are discussed. To counter ZIKV-
associated disease, we need to make rapid progress in developing novel therapies that
work effectually to inhibit ZIKV.
Keywords: Zika virus, drugs, therapies, microcephaly, Guillain-Barré Syndrome
INTRODUCTION
Zika virus (ZIKV) is a mosquito-borne virus belonging to the Spondweni serocomplex in the
genus Flavivirus of the family Flaviviridae that has become a new threat following the Ebola
virus epidemic (Singh et al., 2016). The expanding ZIKV epidemic was declared an emergency
by the World Health Organization on February 1, 2016 (Fajardo et al., 2016; WHO, 2016).
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ZIKV is a single-stranded RNA virus that encodes a single
polyprotein that is cleaved to form mature proteins, i.e., the
capsid, envelope (E), and precursor of membrane and non-
structural proteins. Other flaviviruses such as dengue virus
(DENV), yellow fever virus (YFV), and West Nile virus (WNV)
are closely related to ZIKV. In the last six decades since its
discovery, ZIKV has been considered a mild human pathogen,
but recently it has emerged as threat to global health, showing
increased virulence, rapid spread, and an association with
microcephaly and grave neurological complications like Guillain-
Barré syndrome (GBS) (Cao-Lormeau et al., 2016; Carteaux et al.,
2016; Mlakar et al., 2016; Sarno et al., 2016).
Zika virus has a wide tissue tropism in an experimental rhesus
macaque model, infecting the hemolymphatic system, lymph
nodes, spleen, cardiopulmonary, gastrointestinal, integument,
and genitourinary tissues, along with the adrenal gland, spinal
cord, and cerebrospinal fluid (Coffey et al., 2017). Additionally, it
has been reported in muscles, kidneys, bladders, and in excreted
urine (Gourinat et al., 2015). In males, ZIKV can infect testes
(Govero et al., 2016), prostate and seminal vesicles, explaining
the long-term persistence of viremia in semen, even after virus is
no longer detectable in blood. In the female reproductive system,
virus can be maintained in the vagina, uterus (Hirsch et al., 2017),
vaginal epithelium (mice), and in uterine fibroblasts (Miner and
Diamond, 2017). Miner and Diamond (2017) demonstrated the
wide tissue tropism of the virus in Hofbauer cells, trophoblasts,
and endothelial cells from the placenta. In addition, ZIKV was
found to infect the cornea, neurosensory retina, optic nerve,
aqueous humor, and tears. ZIKV infection in eyes results in
uveitis (Furtado et al., 2016), and the persistence of the virus in
cerebrospinal fluid and lymph nodes appears to enhance activity
of rapamycin (mTOR), proinflammatory, and anti-apoptotic
signaling pathways and reduce extracellular matrix signaling (Aid
et al., 2017).
Zika virus adapts to human hosts by altering NS1 codon usage
to facilitate viral replication and to increase viral titers (de Melo
Freire et al., 2015). Furthermore, ZIKV placental transfer and
its ability to infect neuronal tissue of growing fetuses is evident
(Martines et al., 2016; Mlakar et al., 2016).
The complications of ZIKV infection are intensified by
the unavailability of effective prophylactics, vaccines, or
therapeutics. The spread of ZIKV, which, earlier, was limited to
small geographical areas, has been facilitated by globalization,
unplanned urbanization, poor sanitation, inadequate health
services, and the emergence of insecticide resistance in mosquito
vectors. Mosquitoes, mainly Aedes aegypti and Ae. albopictus,
play a primary role in ZIKV transmission (Musso and Gubler,
2016). In addition, sexual transmission; male-to-female, female-
to-male, and male-to-male transmissions have been reported by
Hamer et al. (2017). A mathematical modeling study conducted
by Gao et al. (2016) indicated that sexual activity contributed to
3.044% of transmission. During the typical incubation period of
2–7 days, despite the relatively low viral loads in people, infected
human patients serve as a source of ZIKV (Foy et al., 2011).
After viremia declines, convalescence begins, during which time
a person is no longer infectious to a mosquito; however, they
remain infective to other human hosts, with a low infection rate.
The convalescent stage ends with establishment of long lasting
immunity (Gao et al., 2016).
Zika virus vaccines in development include inactivated
virus, nucleic acid-based vaccines (DNA or RNA), live vector
vaccines, subunit vaccines, virus-like particles, and recombinant
ZIKV. Because of its devastating effects, effective therapeutic
agents and a vaccine are urgently needed. Presently, there are
several drugs reported to be useful in treating ZIKV, a few
of which are repurposed drugs. Efforts to develop effective
drugs have increased worldwide, and a few compounds are
in phase I trials (Alam et al., 2017; Ali et al., 2017). The
present review discusses recent advances in and prospects for
the design and development of various anti-viral drugs and
therapeutics for ZIKV infection, including the identification of
novel drug targets. The updated information compiled here
will contribute to the design and development of additional
effective drugs and pharmaceuticals to curtain the ill effects of
ZIKV.
ADVANCES IN THE DESIGN AND
DEVELOPMENT OF ANTI-ZIKV DRUGS
AND THERAPIES
Specific anti-viral drugs are not yet available to combat ZIKV.
Acetaminophen is used to control fever and pain, anti-histamines
are used for pruritic rashes, and fluids are administered to
prevent dehydration in ZIKV-infected patients. However, certain
drugs such as acetylsalicylic acid (aspirin) and non-steroidal
anti-inflammatory drugs (NSAIDs) are contraindicated because
they increase the risk of internal bleeding, and other flaviviral
infections, including DENV and chikungunya virus, can cause
hemorrhage (; Mukherjee and Era, 2016; Musso and Gubler,
2016). ZIKV actively replicates in and causes death of neurons.
Research for developing anti-viral drugs for Zika is going on
fast and compounds like Sofosbuvir, 7-DMA, BCX4450, and
NITD008 are currently entering a phase I trial (Ali et al., 2017).
Recently, several drugs and therapeutic candidates have been
explored to determine the most effective treatment regimens to
combat ZIKV and its severe clinical complications, which are
being described in the following sections.
Interferons as Anti-virals
Activation of the innate immune system by viruses leads to
the release of interferons (IFNs), which are responsible for the
elimination of viruses and for immune regulation. In an in vitro
cell culture system developed for ZIKV cultivation, IFN-α, IFN-
β, and IFN-γ have been shown to inhibit viral replication
(Contreras and Arumugaswami, 2016). Type I interferons have
shown dose-dependent inhibition of ZIKV replication in a cell
culture study that used quantitative RT-PCR (Goebel et al.,
2016). The inverse has been documented by Bowen et al. (2017);
they demonstrated ZIKV’s ability to evade in the presence
of type I interferon responses by degrading STAT2 signaling
molecules. Trophoblastic cells secrete IFN-λ1, which exhibits
anti-viral activities against single-stranded RNA viruses. In an
in vitro model, conditioned medium obtained from PHT cells
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has been found to inhibit ZIKV growth in trophoblastic and non-
trophoblastic cells by stimulating the secretion of IFN-λ1 (Bayer
et al., 2016).
Inhibition of Virus Entry into Cells
Inhibition of viral entry into a cell can serve as the first
line of defense against ZIKV infection. ZIKV first binds
to cell receptors, including AXL (Nowakowski et al., 2016),
DC-SIGN, Tyro3, TIM, and TAM (Hamel et al., 2015), and then
enters cells by clathrin-dependent endocytosis. ZIKV entry is
severely hampered in human microglial cell line (CHME3) by
silencing the clathrin heavy chain (a component essential for
clathrin-coated vesicle formation) and dynamin-2 (a GTPase,
required to pinch off endocytic vesicle from the plasma
membrane). TIM receptors mediate viral entry after binding
with viral phosphatidylserine and phosphatidylethanolamine
(Jemielity et al., 2013). TIM1-mediated entry of DENV-2,
WNV, and EBOV is inhibited by duramycin-biotin, which
has less profound hemolytic effects and does not exhibit
cellular cytotoxicity (Richard et al., 2015). The same TIM1
receptors are also involved in ZIKV entry; therefore, these drugs
can be evaluated for the prevention of ZIKV entry. Peptide
(GQASNGVFVIHWGKFDSFGIAV) derived from the Japanese
encephalitis virus (JEV) E protein stem is able to prevent ZIKV
infection with IC50 even at the nanomolar scale (3.93 nM).
It also decreases the viral load and prevents histopathological
damages in brain and testes in AG6 mouse, and attenuates the
inflammatory response (Chen et al., 2017).
Modes of entry of ZIKV and various drugs inhibiting viral
entry and replication have been depicted in Figure 1.
Blocking of Receptor Binding
After screening, more than 2000 molecules for their ability to
inhibit ZIKV replication, nanchangmycin, a polyether obtained
from Streptomyces nanchangensis that possesses insecticidal and
anti-bacterial activity has been shown to block ZIKV replication
in U2OS cells in in vitro. It is considered to act by targeting
AXL receptors and blocking clathrin-mediated endocytosis.
However, the exact mechanism of action of nanchangmycin is
unknown (Rausch et al., 2017). Two small drug-like molecules,
ZINC33683341 and ZINC49605556, both identified through
homology modeling in silico, have been reported to inhibit ZIKV
E protein by binding the viral receptors. Antiviral activities of
ZINC33683341 have been confirmed in in vitro test. Thus, such
viral inhibitors may be candidate molecules for ZIKV drugs after
further research and clinical validation (Fernando et al., 2016).
Inhibition of Endosomal Fusion
Fusion of the endosome to lysosome is a critical step in releasing
virus from endosomes. Obatoclax is a potential anti-neoplastic
and pro-apoptotic synthetic small molecule Bcl-2 inhibitor. Its
mesylate salt is reported to reduce the acidity of endolysosomal
vesicles in in vitro model. Bcl-2 antagonists are effective only
against viruses that require a low pH for fusion and entry,
such as ZIKV, WNV, YFV, and others. Despite this limitation,
Obatoclax works as a broad-spectrum anti-viral agent (Varghese
et al., 2016). However, in clinical phase I and II trials while
treating hematological and myeloid malignancies, Obatoclax did
not produce satisfactory results, possibly due to inadequate
inhibition of Bcl-2 family proteins. Chloroquine, which is an
anti-malarial drug, raises endolysosomal pH and inhibits ZIKV
infection in human brain microvascular endothelial cells, human
neural stem cells, and mouse neurospheres (Delvecchio et al.,
2016). Similarly, SaliPhe, a molecule under pre-clinical study and
vATPase inhibitor, was tested as an inhibitor of endocytosis to
obstruct ZIKV infection (Adcock et al., 2017). Griffithsin, a lectin
isolated from the red alga Griffithsia sp., is a potent flaviviral
entry inhibitor. It can cross-link high-mannose oligosaccharides
present on the viral E glycoproteins and has shown wide anti-viral
activity against HIV (Alexandre et al., 2011), HPV (Levendosky
et al., 2015), HSV (Nixon et al., 2013), HCV (Takebe et al.,
2013), and SARS (O’Keefe et al., 2010). Squalamine, a FDA
approved cationic chemical, which act by disturbing electrostatic
interactions between the virus and host membranes during fusion
and budding (Zasloff et al., 2011), has been found well tolerated
as component of eye drop in clinical studies conducted on human
participants. Therefore, such potent drugs can be used as an
anti-viral agent against ZIKV too.
Inhibition of Virus Replication
The single-stranded RNA genome encodes a polyprotein, which
is proteolytically cleaved into three structural proteins (C,
prM, and E) and seven non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5). The NS5 protein, an
RNA-dependent RNA polymerase, plays an important role in
viral RNA synthesis and inhibits IFN signaling by binding
to STAT2 (Grant et al., 2016). ZIKV NS3 protein exhibits
helicase activity that is essential for viral replication. The helicase
domain of NS3 is activated by GTPγS (triphosphate), which
facilitates the unwinding and translocation of RNA at the time
of replication. The ZIKV helicase, along with NS5, is an attractive
target for ZIKV drug development. Small membrane-associated
interferon-inducible transmembrane proteins (IFITMs) are
intrinsic immune system defenses that are able to inhibit
replication of several pathogenic viruses. Both IFITM1 and
IFITM3 have been reported to inhibit early stages of infection
and replication of ZIKV in HeLa cells with the predominant
role played by IFITM3 (Savidis et al., 2016). Cavinafungin, an
alaninal-containing lipopeptide of fungal origin, has recently
been found to inhibit ZIKV polyprotein processing and cleavage
of host protein signal peptides through inhibition of host
endoplasmic reticulum signal peptidase in in vitro model
(Estoppey et al., 2017). Synthetic 25-hydroxycholesterol has been
shown to inhibit ZIKV entry into the host in an in vivo assay using
mouse and rhesus macaque models (Li et al., 2017). An in vitro
study conducted in Vero cells using compounds such as ribavirin,
CMX001, T-705, and T-1105 showed that T-705 (favipiravir) and
T-1105 were able to reduce cell death caused by ZIKV (Cai et al.,
2017). Thus, these compounds that inhibit ZIKV replication in
cell culture need to be explored further so that they can be used
safely against ZIKV.
Numerous drugs involved in inhibition of virus
replicationhave been portrayed in Figure 2.
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FIGURE 1 | Mode of entry of Zika virus (ZIKV) and various drugs inhibiting viral entry and replication (1) ZIKV binds to cell receptors including AXL, DC-SIGN, Tyro3,
TIM, and TAM. (2) Clathrin-dependent endocytosis. (3) Endosome mediated transport of ZIKV. (4) Fusion of virus membrane with host endosomal membrane, which
depends on the pH. (5) Uncoating (6) The positive-sense genomic ssRNA is translated into a polyprotein, which is cleaved into all structural and non-structural
proteins. Replication occurs at the surface of endoplasmic reticulum in cytoplasmic viral factories. A dsRNA genome is synthesized from the genomic ssRNA(+) (7)
Virus assembly takes place at the endoplasmic reticulum. (8) At the endoplasmic reticulum, virions bud and are transported to the golgi apparatus. (9) In the golgi,
prM protein is cleaved and maturation of the virion takes places. (10) Virions are released by exocytosis. (11) Obatoclax and chloroquineinhibit the acidic environment
of endolysosomal vesicles. Squalamine, a cationic chemical, disturbs the electrostatic interaction between virus and host membranes during fusion and budding.
(12) Cavinafungin, an alaninal-containing lipopeptide of fungal origin, inhibits ZIKV polyprotein processing and also the cleavage of signal peptide of host proteins.
(13) Nanchangmycin, a polyether obtained from Streptomyces nanchangensis; small drug-like molecules, ZINC33683341 and ZINC49605556 block the receptor
thus inhibiting the ZIKV entry. (14) TIM1 mediated entry is inhibited by Duramycin-biotin.
Inhibition of NS5
The flaviviral NS5 protein has two major catalytic domains. The
first domain is the RNA-dependent RNA polymerase (RdRp), and
the second one is a methyltransferase domain (Egloff et al., 2002).
Conserved regions in ZIKV NS5 MTase and RdRp structures
have been identified, so that current anti-virals targeting these
regions in flaviviruses like DENV, WNV, and YFV may be used
against ZIKV (Duan et al., 2017). NS5 is also involved in IFN
antagonism. Mutant ZIKV, which is unable to prevent IFN-
stimulated signaling can grow in IFN-deficient cell lines and
has vaccine potential. Structural analysis of NS5 will provide
information to design small molecule inhibitors that may prevent
NS5-mediated interferon inhibition (Dar et al., 2017).
Inhibition of the RdRp domain
Nucleoside analogs may be incorporated into the viral nascent
RNA chain during RdRp activity, causing premature termination
of RNA synthesis (Kok, 2016). After screening a library of
nucleoside analogs, 2′-C-methylated nucleosides were found to
be most efficient at terminating synthesis because they were
selective for ZIKV, and there was no cytotoxicity or adverse
effects on cellular proliferation observed (Eyer et al., 2016).
These nucleosides do not target the active RdRp site; rather, they
terminate elongation of the nascent viral RNA chain. Another
nucleoside analog, 7-deaza-2′-C-methyladenosine, developed
initially as an HCV replication inhibitor, was also evaluated
for inhibition of ZIKV replication in Vero cells and a mouse
model. Using a mouse model deficient in IFN-α/β and the IFN-
γ receptor (AG129 strain), intraperitoneal inoculation of ZIKV
with approximately 2 plaque-forming units (pfu)/animal resulted
in disease. Inoculated animals were treated with 7-deaza-2′-C-
methyladenosine at a dose of 50 mg/kg/day. The drug delayed
the onset of viremia and virus-induced morbidity and mortality
in infected mice (Zmurko et al., 2016). Despite demonstrating
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FIGURE 2 | Various drugs involved in inhibition of virus replication at different stages. (1) Flaviviral NS5 has two major catalytic domains: RNA-dependent RNA
polymerase (RdRp) and methyltransferase domain. Nucleoside analogs like 2′-C-methylated nucleosides, 7-deaza-2′-C-methyladenosine, Sofosbuvir may
incorporate during the polymerase activity of RdRp in the viral nascent RNA chain and cause premature termination of RNA synthesis. The 2′-fluoro-2-C-methyl-UTP
binds to the active site on NS5. (2) Methyltransferase domain is responsible for transferring mRNA cap. Sinefungin, an adenosine derivative, isolated from
Streptomyces griseoleus, inhibit S-adenosyl-1-methionine (SAM), the natural substrate for methyltransferases and inhibit the methyltransferase activity. (3) Helicase
crystal structure reveals a conserved triphosphate pocket and a positively charged tunnel for the accommodation of RNA. The helicase-activation is inhibited in the
presence of divalent cation, due to extended conformation adopted by GTPγS in such conditions. (4) Tetrapeptide-Boronic acid is a potent inhibitor of NS2B-NS3
protease. Berberine, Myricetin, Epigallocatechingallate binds with affinity to NS3 protease and also inhibit the ZIKV replication. (5) Small-molecule inhibitor ST-148
inhibits capsid. (6) Ribavirin inhibits host inosine monophosphate dehydrogenase and viral polymerase. (7) Repurposed drugs like Chloroquine, azithromycin,
niclosomide are used to treat ZIKV infection.
efficacy in animal models, the drug remained unsuccessful in the
phase I clinical trial conducted. Adenosine analog NITD008 was
found to be effective against flaviviruses including ZIKV in both
in vitro and in vivo studies and exhibited reduced viremia in mice
(Deng Y.Q. et al., 2016). Unfortunately, in pre-clinical animal
testing, it was found to be too toxic to be suitable for human trials.
Sofosbuvir (Sovaldi) is a nucleotide analog inhibitor that
is commercially available for the treatment of chronic HCV
infection. Its active metabolite is 2′-fluoro-2-C-methyl-UTP,
which binds to the active site of NS5 (Reznik and Ashby, 2017). It
has also shown the ability to inhibit ZIKV infection in human
tumor cell lines and human fetal-derived neuronal stem cells
(Bullard-Feibelman et al., 2017; Reznik and Ashby, 2017). In
clinical phase I and II studies, the regimen containing sofosbuvir
was found to be clinically safe and efficacious (Mangia and
Piazzolla, 2014). It is a class B drug and can be used in men
and non-pregnant women to prevent tissue damage. The 2′-C-
ethynyl and 2′-C-methyl analog of 5′-triphosphates were found to
be incorporated by the RdRp of ZIKV and therefore to efficiently
terminate the elongating RNA chain (Lu et al., 2016); hence, they
may be candidate for the design of better anti-virals against ZIKV.
Methyltransferase domain inhibition
The NS5 protein contains methyltransferase, which is responsible
for transferring the mRNA cap. An NS5 methyltransferase null
mutant was found to be lethal for the virus. Targeting the
NS5 methyltransferase structural domains may prevent ZIKV
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propagation (Zhang C. et al., 2016). Structural analysis of ZIKV-
NS5 aided in the identification of methyltransferase inhibitors
based on in silico analysis, which could lead to the identification
of hotspots for drug designing and development of anti-ZIKV
drugs (Coutard et al., 2016; Stephen et al., 2016). Furthermore,
sinefungin, an adenosine derivative originally isolated from
Streptomyces griseoleus, is a potential anti-fungal and anti-
parasitic compound that competitively inhibits S-adenosyl-1-
methionine (SAM), the natural substrate for methyltransferases,
as well as methyltransferase activity. On the basis of structural
computational analysis, sinefungin was able to attach to GTP
and GDP analogs and might be useful in enhancing their affinity
toward the enzyme for greater selectivity and inhibition of ZIKV
replication (Hercik et al., 2017). Severe toxicity was observed with
this drug in animal studies conducted in dogs and goats while its
usage as an anti-parasitic agent (Robert-Gero et al., 1989), which
has hampered its clinical use. Therefore, less toxic and better
tolerated derivatives must be obtained and tested against ZIKV.
Inhibition of NS3 (Helicase)
An NS3 inhibitor can be used to impede ZIKV infection. The
helicase action of NS3 is inhibited by divalent cations that
cause GTPγS to adopt an extended conformation (Cao et al.,
2016). An understanding of the interactions between NS3 and
GTPγS has led to the identification of small molecules that
inhibit ZIKV. The ZIKV helicase crystal structure has revealed
a conserved triphosphate pocket and a positively charged tunnel
that accommodates the RNA. This critical substrate-binding
pocket may be a good target for anti-virals. Tian et al. (2016)
reported that the helicase of ZIKV is closely related to those of
other members of the family Flaviviridae. Therefore, drugs that
target the helicase of these viruses could also be explored for the
control of ZIKV.
Inhibition of the NS2B-NS3 Protease
The crystallographic structure of the NS2B-NS3 protease of
ZIKV indicated that tetrapeptide-boronic acid would be a potent
inhibitor of the NS2B-NS3 protease (Lei et al., 2016). Based
on studies of surface plasmon resonance and the kinetics of
protease inhibition, Lee et al. (2016) identified several small
molecular inhibitors of the protease. In addition, the group
identified a “pre-open conformation” for the ZIKV NS2B-
NS3 protease by X-ray crystallographic analysis. A molecular
docking analysis revealed that berberine, an FDA-approved
quaternary ammonium salt used against DENV, has a high
binding affinity to the NS3 protease of ZIKV (Sahoo et al.,
2016). Further, a ‘Hybrid Combinatorial Substrate Library’
approach has also been used to determine the substrate specificity
of the NS2B-NS3 protease for the design of phosphonate-
containing protease inhibitors (Rut et al., 2016). Lim et al.
(2017) tested 22 plant polyphenolic compounds for their ability
to inhibit Escherichia coli-expressed ZIKV NS2B-NS3 pro-
protease. Inhibition of protease activity was evaluated by a
fluorescence resonance energy transfer-based assay. Among all
compounds tested, myricetin showed the strongest inhibition
of the NS2B-NS3 protease, followed by luteolin, epicatechin
gallate, gallocatechin gallate, and epigallocatechin gallate. CN-
716, a capped peptidomimetic boronic-acid compound, has been
found to form ZIKV NS2B-NS3 protease inhibitor complex,
which might have biological importance in inhibiting ZIKV
replication (Lei et al., 2016). Structural and functional insights
gained through crystallographic techniques will accelerate the
discovery of structure-based anti-ZIKV compounds.
Nucleoside Biosynthesis Inhibitors
Nucleoside biosynthesis inhibitors have broad anti-viral
activities, but limited numbers of such compounds are available
for clinical use. Inhibition of host inosine monophosphate
dehydrogenase (IMPDH) and viral polymerase is the key to
the anti-viral activity of ribavirin against flaviviruses (Crance
et al., 2003). Mycophenolic acid (MPA) is an IMPDH inhibitor
and exhibited potent dose-dependent anti ZIKV activity
(EC50 of <0.32 µM) in cell culture experiments that were
confirmed using qRT-PCR (Goebel et al., 2016). Contrary to
the above finding, Adcock et al. (2017) found MPA to be not
very effective (EC50 >50 µM) with observation of significant
cytotoxicity and cytopathogenic effects in a high-throughput
assay. Dihydroorotate dehydrogenase (DHODH), a host enzyme
which is responsible for pyrimidine biosynthesis, is a possible
enzyme target for antiviral research. Brequinar, an inhibitor of
this enzyme, exhibited anti-ZIKV activity with an EC50 (half
maximal effective concentration, which is a common measure
of a drug’s potency; the lower the EC50, the more effective the
drug is) at submicromolar levels, but a low therapeutic index for
Brequinar has restricted its clinical use.
Capsid inhibition
In comparison with targeting E protein, the capsid has gained
less research attention. It is a dimeric protein with a positively
charged surface and hydrophobic core pocket. A single small-
molecule inhibitor (ST-148) has been identified, which, despite
poor oral bioavailability, was shown to decrease the viremias
and viral loads of DENV-1–4, Modoc virus, YFV, and HCV.
ST-148 was screened in a panel of 20,000 chemically diverse
molecules using a high-throughput assay. It is non-mutagenic
and selectively inhibits flaviviruses (Byrd et al., 2013). ST-148
mediates the self-interaction of capsid proteins and imposes
structural rigidity, disturbing the assembly and disassembly of
DENV particles (Scaturro et al., 2014). The concept of capsid
protein stabilization may also be applicable to ZIKV.
Computer-Aided Drug Design
Before clinical studies, there are three essential phases of
research: high-throughput computer or in silico drug design,
medium-throughput in vitro drug testing, and low-throughput
in vivo drug testing (Basak and Nandy, 2016). Understanding
the ZIKV structure would aid in designing anti-viral therapies
to curtail ZIKV infections (Cox et al., 2016). ZINC64717952
and ZINC39563464 have been found to block MTase and
RdRp, respectively, based on a computational docking analysis
(Ramharack and Soliman, 2017). The NS5 polymerase was
inhibited by an andrographolide from Andrographis, whereas
bisabolol and levomenol from Matricaria recutita and Myoporum
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crassifolium, respectively, blocked NS3 protease in virtual
screening (Feranchuk et al., 2016). In silico techniques to identify
enzyme blockers allow simultaneous assessments of various
compounds with limits financial or experimental resource costs.
A virtual screen of 36 million compounds from the MCULE
database led to the selection of two molecules, MCULE-
8830369631-0-1 and MCULE-9236850811-0-1, with inhibition
constant (Ki) values of 0.08 and 0.30 µm, respectively (Onawole
et al., 2017).
OpenZika, an IBM world community grid project, was used to
identify drug molecule docking for various ZIKV structures. This
platform allows data to be shared with researchers worldwide
to facilitate the speedy discovery of anti-ZIKV drugs (Ekins
et al., 2016). To elucidate therapeutically essential components
like siRNAs, miRNAs, and sgRNAs (CRISPR/Cas9 targets)
for ZIKV, an integrative multi-omics platform, ZikaVR1, is
available. This platform offers other functions, including whole-
genome alignment, codon information and bias assessments,
phylogenetic deduction, and information regarding glycosylation
sites and primer design (Gupta et al., 2016). The therapeutics
based on enzyme, nucleoside, and capsid inhibitors are currently
in their infancy and much more work needs to be carried
out to bring these to clinical grounds. Computational analysis
allows high throughput screening of potentially active molecules,
however, in vivo validation is a prior requisite to move them from
bench to bedside.
Drug Repurposing
Drugs take decades to develop and test for efficacy and safety.
Since there is presently no approved vaccine or drug available for
ZIKV, the major focus of researchers, therefore, is on attempting
drug repurposing. Scientists are evaluating repurposing of several
FDA approved drugs against ZIKV infections. In this direction, a
few promising drug candidates have been shortlisted by adapting
various screening methodologies. For example, chloroquine, a
4-aminoquinoline, readily increases the pH of acidic vesicles
(Akpovwa, 2016) and inhibits a conformational change essential
for fusion between the virus envelope and endosomal membrane
(Smit et al., 2011). In vitro studies revealed that chloroquine
decreases the number of ZIKV-infected neural cells in different
cell models and protects cellular death (Delvecchio et al., 2016).
Other anti-malarial drugs such as quinacrine, mefloquine, and
GSK369796 also demonstrate anti-ZIKV activity by inhibiting
autophagy (Balasubramanian et al., 2016). During the screening
of a library of FDA-approved drugs, both established anti-
virals like bortezomib and mycophenolic acid and compounds
with no previously reported anti-viral activity (e.g., daptomycin)
were found to inhibit ZIKV replication in human cervical,
placental, neural stem, and primary human amniotic cells
(Barrows et al., 2016). Xu M. et al. (2016) screened a panel of
compounds containing FDA-approved drugs, drugs in clinical
trials, and pharmacologically active compounds to suppress
infection-induced caspase activity. Human neural progenitor
cells and glial SNB-19 cells infected with ZIKV were used as
models to quantify ZIKV-induced caspase-3 activity. Of these
1http://bioinfo.imtech.res.in/manojk/zikavr/
compounds, a pro-caspase inhibitor, emricasan, successfully
protected both neural cell monolayers and three-dimensional
organoid cultures of neural cells by decreasing ZIKV-induced
caspase-3. Similarly, screening of 725 FDA-approved chemically
diverse compounds in ZIKV-infected Huh7 cells at a 20-µM
concentration led to the selection of lovastatin, a drug used to
reduce cholesterol; 5-fluorouracil used as a cancer treatment;
6-azauridine, a broad-spectrum antimetabolite; palonosetron,
which is used to treat chemotherapy-induced nausea and
vomiting; and kitasamycin, a macrolide antibiotic. The selection
criteria included a selectivity index, maximum activity, and the
EC50 of compounds (Pascoalino et al., 2016).
Niclosamide, clinically given to treat helminths inefction, can
protect ZIKV-infected cells and inhibit virus replication (Xu M.
et al., 2016). Bortezomib and sorafenib are anti-cancer drugs
possessing anti-viral activity and have been well tolerated in
phase I clinical trials (Cheng et al., 2016). Azithromycin, a
commercially available antibiotic, was also found to inhibit ZIKV
proliferation in cultured brain cells, suggesting a possibly drug to
prevent GBS and microcephaly (Retallack et al., 2016). Recently,
bromocriptine, a drug indicated for the treatment of pituitary
tumors, Parkinson’s disease, and type 2 diabetes, was shown
to inhibit ZIKV replication in vitro, possibly by occupying the
active site of the ZIKV-NS2B-NS3 protein. A fluorescence-based
enzymatic assay also revealed that bromocriptine inhibits the
activity of the ZIKV-NS2B-NS3 protease, possibly by occupying
the active site pocket. In addition, bromocriptine, along with type
I interferon, exhibits synergistic anti-ZIKV activity (Chan et al.,
2017). Suramin is an approved drug used to treat trypanosomal
human sleeping sickness and is available for prophylactic and
therapeutic uses in children. It inhibits the early steps of ZIKV
binding/entry and decreases the number of infectious ZIKV
progeny virions (Albulescu et al., 2017; Tan et al., 2017). The
safe pediatric anti-protozoan and anti-viral drug nitazoxanide
was found to affect post-attachment steps of ZIKV infection at
or below a 10 µM dose (Cao et al., 2017). The anti-ZIKV activity
of nitazoxanide is not less than that of niclosamide (Xu M. et al.,
2016), but poor absorption of niclosamide might reduce its utility.
Hyperactivation of the N-methyl-D-aspartate receptor
(NMDAR), mediated by enhanced glutamate release, may
result in the accumulation of high levels of Ca2+ in neurons,
and this may further lead to apoptosis or necrosis of neural
cells. Neurodegeneration in ZIKV disease possibly occurs due
to the excitotoxicity of glutamate. FDA approved NMDAR
antagonistic drugs to treat Alzheimer’s disease (namely
memantine, MK-801, agmatine, and ifenprodil) were found
to prevent neuronal cell death caused by ZIKV under in vitro
conditions without reducing viral titers (Costa et al., 2017).
Memantine was found to bind non-competitively with NMDAR,
while blocking only the pathologically active NMDAR and
leaving its physiological activity unaffected (Sirohi and Kuhn,
2017). Memantine is also listed in pregnancy category B drugs
by the FDA, hence it could be used safely to reduce neurological
complications associated with ZIKV infection (Sirohi and Kuhn,
2017). Practical usage of repurposing earlier approved drugs
could help in formulating fascinating approaches to counter
ZIKV and its associated complications for which purpose
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more research work is needed before moving into clinical
trials.
Development of Pregnancy-Safe Drugs
The ability of ZIKV to infect fetuses and cause severe disease
requires the development of drugs that function during
pregnancy and that are safe for both the pregnant mother and
fetus. The drugs must be able to cross the placental barrier to
reach the fetus and to cross the blood-brain barrier to reach
neural cells, the main targets of ZIKV. Khandia et al. (2017)
summarized FDA-approved category B drugs (adequate animal
study data shows no risk to fetuses, but controlled studies
on pregnant women are unavailable) and category C drugs
(animal studies revealed few teratogenic effects on fetuses, but
control studies on pregnant women are unavailable; however, the
potential benefits of using the drug may outweigh the risks). The
list contains several drugs including the FDA category B drugs
sofosbuvir (Sacramento et al., 2017), azithromycin (Retallack
et al., 2016), niclosamide (Xu M. et al., 2016), palonosetron
(Pascoalino et al., 2016), mefloquine (Balasubramanian et al.,
2016), and daptomycin B (Barrows et al., 2016), category C drugs
chloroquine (Delvecchio et al., 2016), amodiaquine, quinacrine
hydrochloride (Balasubramanian et al., 2016), auranofin,
clofazimine, deferasirox, methoxsalen, micafungin, sertraline-
HCl, fingolimod, ivermectin, digoxin (Barrows et al., 2016), and
seliciclib (Xu M. et al., 2016), which could be repurposed for
treating ZIKV infection.
Use of Convalescent Serum
Recently, neutralizing activity of human convalescent serum
against ZIKV has been demonstrated in a standard plaque
reduction neutralization test (Li et al., 2016). Further, a decreased
number of ZIKV-infected brain cells in ICR albino fetal mice
were observed after treating pregnant mice intraperitoneally
with convalescent serum. Furthermore, ZIKV-mediated caspase
activity was reduced, indicating the utility of convalescent serum
in limiting ZIKV infection and cell death. Convalescent serum
also reversed thinning of the cortical plate (CP) and ventricular
zone (VZ)/subventricular zone (SVZ) observed in the brains
of ZIKV-infected fetal mice. Therefore, the use of convalescent
serum for the treatment of ZIKV-infected pregnant women and
whether it can protect against brain abnormalities in fetuses
should be assessed. A study by Wang S. et al. (2016) demonstrated
the suppression of ZIKV infection in pregnant mice with a
reduction in caspase-3-activated cells using convalescent serum
with high amounts of neutralizing antibodies. Convalescent
serum also inhibited progenitor cell death in infected fetal
brain tissue, thereby preventing microcephaly. ZIKV-confirmed
convalescent human serum was able to neutralize multiple
strains of infectious ZIKV or ZIKV RVPs, indicating that
ZIKV is circulating as a single serotype (Wang S. et al., 2016).
Additionally, antibodies present in convalescent serum can cross
the placental, as well as the blood-brain barrier, of fetuses; thus,
it is a good candidate for the treatment of infected pregnant
women.
The convalescent serum should be free from ZIKV and
other blood-borne pathogens prior to transfer, therefore heat
treatment at 58.0 ± 1.0◦C for 590 ± 10 min or solvent/detergent
(S/D) treatment is commonly employed. S/D treatment with 1%
(wt/wt) tri-n-butyl phosphate (TBP) and 1% (wt/wt) octoxynol-9
at 30.0± 1.0◦C and pH 6.9–7.4 for 60 min completely inactivated
ZIKV (Kühnel et al., 2017). A photochemical, amotosalen,
quickly intercalates into DNA and RNA strands and forms
covalent adducts with pyrimidine, thereby inhibiting replication
and transcription of the virus. Plasma samples treated with
amotosalen and UVA-light are safe for use in patients, as they
are free from viable ZIKV particles, even in the presence of a
detectable amount of ZIKV viral RNA (Aubry et al., 2016).
Use of Neutralizing Antibodies
A human monoclonal (mAb) antibody against DENV named C10
has been found to neutralize ZIKV E protein. Using an electron
microscope, C10-ZIKV interactions were studied in extracellular
(pH 8), early (pH 6.5), and late endosomal (pH 5.0) stages. At
all of the tested pHs, C10 bound ZIKV E protein at different
positions. At pH 8.0, it bound at the intradimer interface; at
pH 6.5, it bound the virus surface; and at pH 5.0, it blocks
raft structure. Of note, different structural rearrangements of the
virus were blocked by C10 antibodies as depicted in visualization
under electron microscope (Zhang S. et al., 2016), suggesting
its broad applicability at different stage of infection. Out of the
panel of human mAbs derived from patients previously infected
with ZIKV, ZIKV-117 mAb was found to broadly neutralize
the African and Asian-American lineages of ZIKV. The mAb
recognized the unique quaternary epitope on the E protein
dimer-dimer interface and effectively reduced ZIKV infection,
maternal-to-fetal transfer, and tissue pathology and mortality
(Sapparapu et al., 2016).
Three-dimensional cryo-electron microscopy showed
that ZIKV-117 Fabs cross-link with monomers in surface E
glycoprotein dimers and between neighboring dimers, thereby
preventing the structural reorganization of E protein monomers
and requiring the formation of fusogenic E protein trimers
(Hasan et al., 2017). Neutralizing antibody 2A10G6, which
targets the highly conserved fusion loop region of flavivirus E
proteins, binds with high affinity and can neutralize ZIKV in a
mouse model (Dai et al., 2016). Moreover, of 13 human mAbs
from a single ZIKV patient, two mAbs (Z23 and Z3L1) potently
bound and neutralized ZIKV, but it did not cross react with any
DENV strains (Wang Q. et al., 2016).
Strategies to Limit Antibody-Dependent
Enhancement (ADE)
Studies regarding the phenomenon of antibody-dependent
enhancement (ADE), in which viremia is increased in the
presence of pre-existing cross-reactive, poorly neutralizing
antibodies against a heterologous flavivirus strain, are
controversial. In few cases, pre-existing cross-reactive antibodies
have shown to increase ADE, while in some experiments
such antibodies exhibited therapeutic potential. For instance,
preincubation of human myeloid cells (U937), which are poorly
permissive for ZIKV, with convalescent serum obtained from
subjects who resolved DENV infections, resulted in increased
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ZIKV infectivity (Dejnirattisai et al., 2016). These results were
confirmed by Charles and Christofferson (2016), who used a
DENV serotype 2-derived mAb (4G2) to demonstrate ADE
in ZIKV infections. A contradictory finding is reported by
Pantoja et al. (2017) who reported reduction in viremia in
DENV-exposed rhesus macaques, when compared with naïve
animals. Antibodies to WNV have also shown cross-reactivity
with ZIKV E protein, resulting in viremias that were at least 35-
fold higher than those of the controls, and studies to determine
the role of anti-WNV antibodies in enhancing ZIKV revealed
a pattern like that observed with anti-DENV antibodies. WNV
may enhance ZIKV in vitro as well as in vivo; however, the
amplitude of enhancement is less than that of DENV (Bardina
et al., 2017). Because 4G2 is widely used as an anti-flavivirus
mAb, the possibility of using this mAb for other flaviviruses such
as JEV and YFV or to limit WNV mediated ADE of ZIKV should
be considered.
The two EDI/II cross-reactive mAbs developed against ZIKV
(ZKA78) and DENV (DV82) were tested for their capacity for
ADE of DENV and ZIKV infection in animal models. Further,
in an AG129 mouse model, wild-type mAbs ZKA78 and DV82
(without the LALA mutation), when administered prior to
DENV-2 infection, resulted in severe disease and death of mice on
the 5th day post-infection, suggesting that the DENV infections
were affected by the presence of pre-existing ZIKV antibodies
(Stettler et al., 2016). However, antibodies against the envelope
dimer epitope 1 (EDE1) region were shown to neutralize ZIKV,
in addition to all four DENV serotypes, indicating their potential
immune-therapeutic potential in ZIKV infections (Swanstrom
et al., 2016). The mouse mAb 2A10G6 reported to bind the
conserved 98DRXW101 motif of the FL loop is a broadly
neutralizing antibody. It not only neutralizes DENV1-4, but also
protected A129 mice against ZIKV infection (Dai et al., 2016).
Hence, it seems that the antigenic epitopes against which the
antibody is generated is the deciding factor in developing/not
developing ADE. The epitopes resulting in poor neutralization
lead to ADE, while the strongly neutralizing antibodies have
therapeutic potential. Information regarding common epitopes
may be useful in determining strategies to limit ADE (Xu X. et al.,
2016).
To develop therapeutic mAb candidates, LALA mutations in
the Fc region of antibodies have been examined (Figure 3). The
LALA mutations are a leucine (L)-to-alanine (A) substitution at
positions 234 and 235 (LALA) in the Fc region of IgG antibody.
The binding of the Fc region of an antibody with gamma
receptors (FcγRs), expressed on various immune cells, triggers
their effector function. In the case of ZIKV or DENV, the virus-
antibody immune complex is internalized by FcγRs and can
result in ADE. Introduction of the LALA mutations into the Fc
region abolishes its ability to bind to FcγRs (Arduin et al., 2015).
Such engineered antibodies are incapable of interaction with
FcγRs and hence eliminate ADE from prior DENV infections
in vitro and in vivo (Williams et al., 2013).
Anti-ZIKV mAbs with the LALA mutation have been
engineered for therapeutic and prophylactic purposes. The
EDIII-specific neutralizing mAb ZKA64, which has the LALA
mutations in the Fc region, blocked ADE in ZIKV infections
in K652 cells in the presence of convalescent serum and
completely protected A129 mice from lethal ZIKV challenge
when administered one day prior to or post challenge (Stettler
et al., 2016). Given the high potency and in vitro and in vivo
efficacy of LALA mutant neutralizing antibodies, creation of
such mutants appears to be a safe and promising approach
to inhibit ADE in patients living in areas which co-circulating
flaviviruses. The LALA mutations and substitution at amino
acid position 297 (N297A) in the Fc region of an antibody
reduces binding with FcγRs and C1q complement. Thus, such
engineered antibodies may play an important role in therapeutics
and prophylaxis (Arduin et al., 2015). DENV human mAb SIgN-
3C, which strongly neutralizes ZIKV when the LALA mutations
are introduced, did not induce ADE, showed a reduced viral
load in fetal organs, and prevented virus-induced fetal growth
retardation. This indicates the prophylactic potential of the
antibody (Kam et al., 2017). In addition, mAbs such as Z23 and
Z3L1 (mentioned in above section), which specifically neutralize
ZIKV only and neither bind to nor neutralize any of the four
DENV serotypes, are also of great importance in limiting ZIKV-
associated ADE. In fact, a patent has been granted to Baehner
et al. (2015), who modified the Fc region of human antibody,
reducing its affinity for FcγRs by 1.15 to 100 folds and resulting
in the inhibition of signaling cascades that lead to downstream
immune response such as ADE in the case of DENV and ZIKV
infection.
Use of Herbal Drugs
Herbal drugs are of increasing interest because of the
development of anti-microbial resistance in microbes and
owing to their cost effectiveness. Curcumin, a common food
additive, is able to reduce ZIKV infectivity by hindering the
virus binding to host cell in a dose- and time-dependent manner,
without having adverse effects on cellular viability (Mounce et al.,
2017). Recently, a Chinese semi-synthetic formulation from
Andrographis paniculata named xiyanping, in combination with
other antiviral and symptomatic treatments was administered
to treat Zika fever in a patient admitted in Ganxian People’s
Hospital. The patient recovered within 7 days after starting
treatment that included this medication (Deng Y. et al., 2016).
Quercetin, a flavonoid present in fruits, vegetables, leaves, and
grains, has been found to inhibit Zika NS2B-NS3pro enzymatic
activity in a dose-dependent manner. Commercially available
quercetin has been reported to inhibit the ZIKV protease with an
IC50 of 26.0± 0.1 µM (Roy et al., 2016).
In vitro studies with a polyphenol, (_)-epigallocatechingallate
(EGCG), found in green tea have shown inhibition of ZIKV
(Carneiro et al., 2016). The structures of ZIKV NS2B-NS3
protease, NS3 helicase, NS5 methyltransferase, and NS5-RdRp
were generated by homology modeling using the BLOSUM80
scoring matrix by Byler et al. (2016) and molecular docking
with virtual library of phytochemicals was carried out. Out of
2263 plant-derived secondary metabolites tested, 43 compounds
docked with at least one of the ZIKV enzymatic proteins. Some
of these include balsacone B from Populus balsamifera, kanzonol
V from Glycyrrhiza glabra, cinnamoylechinaxanthol from
Echinacea, cimiphenol from Actaea racemosa, and rosemarinic
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FIGURE 3 | Antibody-dependent enhancement (ADE) of Zika virus (ZIKV) and strategies to limit it. (A) General ADE mechanism. (1) FcγRs are receptors present on
the surface of various immune cells. Binding of antibody along with ZIKV results in (2) internalization of immune complexes into cells, (3) a reduction of IL12, TNFα,
and IFNγ expression levels, and (4) increased levels of IL6 and IL12 (5). IL10 acts in an autocrine manner and binds to its own receptor (6), inhibiting the JAK-STAT
pathway (7), which leads to reduced IRF1 production (8) and reduced IFN-stimulated response element (IRF1) production, resulting in decreased nitric oxide
production. Nitric oxide, a diffusible radical antimicrobial and anti-viral, is reduced (9), which results in an increase in the number of infectious virus particles (10)
IFNα/β are inhibited (11), diffuse out from the cell (12), and bind to their own receptors to reduce JAK-STAT signaling. (B) Antibodies engineered to prevent ADE (12)
Engineered antibodies having LALA mutations in their Fc region are able to neutralize virus but fail to bind to FcγRs, thus preventing ADE.
TABLE 1 | Patents of novel innovations useful for the treatment of various flaviviral diseases [readily adaptable for Zika virus (ZIKV) treatment].
S. No. Patent title Patent number Date of
publication/Application
Legal Status Inventors’ Reference
1. Carba-nucleoside analogs for
antiviral treatment
WO2009132123A1 29.10.2009 Application Cho et al., 2009
2. Carba-nucleoside analogs for
antiviral treatment
US8012942B2 06-09-2011 Granted Butler et al., 2001
3. Inhibitors of Flaviviridae viruses WO2011088345A1 21.07.2011 Application Canales et al., 2011
4. Compositions and methods for
treatment of viral diseases
WO2008033466A2 20.03.2008 Application Johansen et al., 2008
5. Antiviral agents for treatment of
Flaviviridae infections
US20040266723A1 30.12.2004 Application Otto et al., 2004
6. Methods and compositions for
treating Flaviviruses and
Pestiviruses
US6812219B2 02.11.2004 Granted LaColla and Sommadossi, 2004
7. Compounds and
pharmaceutical compositions
for the treatment of viral
infections
US7951789B2 31.05.2011 Granted Sommadossi et al., 2011
8. Antibody Fc variants US 8969526 B2 03.03.2015 Granted Baehner et al., 2015
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TABLE 2 | Therapies available/ possible for ZIKV treatment.
S. No. Strategy to
combat ZIKV









Positively charged tunnel for the
accommodation of RNA
Inhibit ZIKV replication – Tian et al., 2016
2. Inhibitors of
NS3 protein
Protease activity essential for its
replication
Inhibit ZIKV replication – Sahoo et al., 2016
Presence of divalent cation Inactivation of helicase domain by extended
conformation of GTPγS




Phosphonate inhibitor Inhibit ZIKV replication – Rut et al., 2016
4. Inhibition of viral
entry
Obatoclax Inhibit acidic environment in endolysosomal
vesicles
– Varghese et al., 2016
ZINC33683341 and
ZINC49605556
Bind with viral receptor and inhibit entry – Fernando et al., 2016
5. Nucleoside
inhibitors
2′-C-methylated nucleosides Cause premature termination of RNA synthesis Kok, 2016
7-deaza-2′-C-methyladenosine – Zmurko et al., 2016
Sofosbuvir B Govero et al., 2016
2′-C-ethynyl analog of
5′-triphosphates
– Lu et al., 2016
Active metabolite
2′-fluoro-2-C-methyl-UTP
Bind to active site present on NS5 – Reznik and Ashby, 2017
NITD008 adenosine analog Cause premature termination of RNA synthesis – Deng Y.Q. et al., 2016
6. Interferon Type I interferons- IFN-α and IFN-β Antiviral defense system inhibits ZIKV replication – Schneider et al., 2014
Human trophoblast (PHT) cell
culture conditioned media secreting
type III IFN and IFN-λ1
Inhibit ZIKV replication – Bayer et al., 2016






Reduce ZIKV infection, maternal to fetal transfer
and tissue pathology
– Sapparapu et al., 2016
mAb 2A10G6 to FLE region Protect from ZIKV infection in vivo – Dai et al., 2016
mAb ZIKV-117 to E region Broadly neutralize several ZIKV lineages. –
mAb Z23 and Z3L1 Inhibit ZIKV replication –
mAb C10- against E region Inhibit ZIKV replication – Zhang S. et al., 2016
8. Convalescent
serum
Polyclonal neutralizing high titer
serum
Reduction in caspase activity – Li et al., 2016
Prevent thinning of the cortical plate (CP) and
ventricular zone (VZ)/ subventricular zone (SVZ)
–
Prevention of neural progenitor cell death in
infected fetal brain tissue and prevention of
microcephaly
– Wang Q. et al., 2016
9. Drug
repurposing
Niclosamide Inhibit ZIKV replication B Xu M. et al., 2016
PHA-690509 Cyclin-dependent kinase (CDK) inhibitor studied
for use in treating cancer; Known to interfere
with gene expression
D Barreyro et al., 2015;
Xu M. et al., 2016
Emricasan Protect brain cells of developing fetuses against
viral damage by inhibiting apoptosis
– Xu M. et al., 2016
Seliciclib Cyclin-dependent kinase (CDK) inhibitor D Xu M. et al., 2016
Bortezomib Replication inhibition in human cervical,
placental, neural stem and primary human
amniotic cells
D Barrows et al., 2016
Mycophenolic acid D
Auranofin unknown C
Vermectin Antiparasitic; inhibits viral protein functioning C Mastrangelo et al., 2012;
Barrows et al., 2016
Daptomycin Cause bacterial membrane depolarization and
a potassium ion efflux.
B Silverman et al., 2003;
Barrows et al., 2016
(Continued)
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TABLE 2 | Continued
S. No. Strategy to
combat ZIKV




Sertraline Inhibit phospholipase A1 and phospholipase D C Rainey et al., 2010;
Barrows et al., 2016
Pyrimethamine Dihydrofolate Reductase Inhibitor and block
purine and pyrimidine synthesis
C Barrows et al., 2016
Cyclosporine A Immunosuppression by selectively inhibiting
cytokine-induced DNA binding of activator
protein-1 and NF-κB.
C Doller et al., 2007;
Barrows et al., 2016
Azathioprine Inhibits purine synthesis D Lennard, 1992;
Barrows et al., 2016
Vinblastine Anticancer; Microtubule inhibitor D Kouznetsova et al., 2014
Vinorelbine/Navelbine Anticancer Microtubule inhibitor D
Vincristine Anticancer Microtubule inhibitor D
Nocodazole Anticancer Microtubule inhibitor –
Sunitinib Anticancer Kinase inhibitor D
Toremifene Anticancer Estrogen receptor modulator D
Daunomycin AnticancerTopoisomerase Inhibitor D
Clemastine Antiallergic, hay fever, rhinitis histamine
antagonist
B
Digoxin Antiarrhythmic Na+-K+ pump inhibitor C
Colchicine Primary for gout, microtubule inhibitor C
Propafenone Antiarrhythmic sodium channel blocker C
Dronedarone Antiarrhythmic multichannel blocker X (not for use in
pregnancy)
Maprotiline Antidepressant adrenergic uptake inhibitors and
histamine antagonist
B
Thiothixene Antipsychotic dopamine antagonist –
Clomipramine Antidepressant serotonin uptake inhibitors and
histamine antagonist
C
Trifluoperazine Antipsychotic, antiemetic dopamine antagonist –
Benztropine Anticholinergic, antihistamine histamine
antagonist and cholinergic antagonist
B2
Azithromycin Antimicrobial protein synthesis inhibitor B
Clarithromycin Antimicrobial protein synthesis inhibitor C
Mebendazole Antihelminthic microtubule inhibitor C
Albendazole Anthelmintic microtubule inhibitor C
Azithromycin Antibacterial B Retallack et al., 2016
Quinacrine, Mefloquine, and
GSK369796
Antimalarial drug inhibiting autophagy C Balasubramanian et al.,
2016
Sinefungin Antifungal antibiotic Not approved Hercik et al., 2017
Suramin African trypanosomiasis Not approved Albulescu et al., 2017
Nitazoxanide Antiprotozoan drug B Cao et al., 2017
Memantine For treating Alzheimer’s Diseases B Costa et al., 2017
Kitasamycin Broad spectrum antimicrobial; – Saiz and Martín-Acebes,
2017
Lovastatin Inhibits cholesterol 247 biosynthesis. X
Nordihydroguaiaretic acid Anticancer drug Not apporoved
PF-429242 Impairs the onset of HCV infection. –
Fatostatin Fat synthesis blocker –
6-azauridine Inhibits de novo pyrimidine synthesis D Adcock et al., 2017
Finasteride For treatment of benign prostatic hyperplasia X
Mycophenolic acid Immunosupressant D Goebel et al., 2016
(Continued)
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TABLE 2 | Continued
S. No. Strategy to
combat ZIKV













Broad spectrum antiviral activity – Parida et al., 2002;
Jiang et al., 2005;
Apostol et al., 2012;
Sriwilaijaroen et al., 2012;
Tang et al., 2012;
Ching et al., 2016;
Saxena et al., 2016
Anti-inflammatory drugs +
Andrographispaniculata
Inhibit ZIKV replication – Deng Y.Q. et al., 2016




Inhibition of NS3 protease –
Epigallocatechin gallate (EGCG)
found in green tea
Inhibitory effect (Inhibition through yet unknown
mechanisms)
– Carneiro et al., 2016
Quercitin and myricetin (flavonoid) Allosteric inhibition of NS2B-NS3 protease – Lim et al., 2016, 2017;
Roy et al., 2016
Balsacone B, kanzonol V,
cinnamoylechinaxanthol,
cimiphenol and rosemarinic acid
Inhibitory effect (Inhibition through yet unknown
mechanisms)
– Byler et al., 2016
11. Other strategies Methyltransferase inhibitors Inhibition of NS5 – Stephen et al., 2016
Methyltransferase inhibitor-
QL-XII-47 and QL-XII-54
Inhibition of viral protein expression – de Wispelaere et al.,
2016
Bithionol Inhibition of caspases C Leonardi et al., 2016
Amotosalen combined with UVA
light
Viral inactivation – Aubry et al., 2016
Metadichol Binds to Vitamin D receptor and displays virus – Raghavan, 2016
acid from Rosmarinus officinalis. Such common medicinal plants
may serve as a source of herbal anti-virals. Such studies encourage
the findings of structure-based drug (Byler et al., 2016). Several
bioactive components, including alkaloids, flavonoids, saponins,
tannins, terpenoids, essential oils, and herbs, such as Azidarachta
indica and Tinospora cordifolia, have shown anti-flaviviral
activities against DENV, JEV, and YFV infections. Such antiviral
agents can also be explored for their efficacy against ZIKV and be
used as complementary alternative medicine (Parida et al., 2002;
Kiat et al., 2006; Meneses et al., 2009; Tang et al., 2012; Roy et al.,
2015; Ching et al., 2016; Gómez-Calderón et al., 2017).
Compounds used for the treatment of various flaviviral
diseases that are readily adaptable to ZIKV are presented in
Table 1.
Other Strategies
Certain compounds such as QL-XII-47 and QL-XII-54 are
quinolines (covalent inhibitors of DENV) that act by inhibiting
viral E and NS5 protein expression without significantly affecting
the host housekeeping protein GAPDH. Due to structural
similarities between flaviviral E and NS5 proteins, similar
compounds can be employed to combat ZIKV infection (de
Wispelaere et al., 2016). Host caspases have been found to
mediate the lethality of multiple pathogenic agents, based on
the HapMap Project of B lymphoblastoid cells from a cohort
of persons of African, European, and Asian ancestry. Bithionol
(an FDA-approved drug) inhibits caspases and has been found
to be effective in reducing the negative effects of ZIKV and
bacterial and plant toxins. Thus, elucidation of such host proteins
that further disease can be used to design drugs for ZIKV
(Leonardi et al., 2016). Nordihydroguaiaretic acid (NDGA) alters
the lipid metabolism of a host by intervening in the sterol
regulatory element binding protein (SREBP) pathway. More
recently, inhibitors of the SREBP pathway, including NDGA and
its methylated derivative tetra-O-methyl nordihydroguaiaretic
(M4N), PF-429242, and fatostatin, have also been found to reduce
WNV and ZIKV replication. These drug candidates may serve
as effective anti-viral agents against ZIKV (Merino-Ramos et al.,
2017).
After ZIKV binds to nerve cells, Toll-like receptor (TLR)-3 is
activated, leading to the dysregulation of genes participating in
neurogenesis, axon guidance, and differentiation. TLR3 agonist
poly (I:C) and thiophenecarboxamidopropionate compounds act
as high-affinity competitive inhibitors of TLR3, and prevented
a reduction in the size of ZIKV-treated neurospheres (Dang
et al., 2016). Metadichol, a nanoemulsion of policosanols, binds
to the Vit D receptor and stimulates the immune system. It can
displace viruses bound to the Vit D receptor, thereby blocking
viral entry into host cells. Metadichol has shown activity against
ZIKV, EBOV, SARS coronavirus, JEV, WNV, and YFV. It is sold
as a nutritional supplement in some Asian countries and is well
tolerated; hence, it can be used as a safe and broad-spectrum
Frontiers in Microbiology | www.frontiersin.org 13 August 2017 | Volume 8 | Article 1469
fmicb-08-01469 August 2, 2017 Time: 17:39 # 14
Munjal et al. Drugs and Therapies Countering Zika Virus
anti-viral agent (Raghavan, 2016). Similarly, testing of other
broad-spectrum anti-viral agents for anti-ZIKV activity will aid
in rapid drug discovery to combat this virus.
An overview of recent advances in the design of drugs and
therapies for ZIKV is presented in Table 2.
A few recent therapies include cytokines, TLRs, siRNA, RNA
interference, probiotics, immunomodulatory interventions, and
nanodrug delivery. These approaches have gained momentum
and are being examined for optimum benefit and safety in
humans and their companion animals. Prospective aspects
of these valuable therapies could be given a due focus for
designing and developing effective drugs, medicines, therapeutics
and immunomodulatory pharmaceuticals for the treatment of
ZIKV infections. Molecular and genetic analyses for a more in-
depth understanding of ZIKV pathogenesis would facilitate the
identification of novel targets and development of safer and more
effective drugs to counter ZIKV effectively.
CONCLUSION AND FUTURE
PERSPECTIVES
Zika virus, an arbovirus, shares several characteristic features
with other members of the Flavivirus family Recent evidences
of autoimmune complications (GBS) and maternal-to-fetal
transmission of virus leading to microcephaly has accumulated.
Using state-of-the-art methods to formulate effective diagnostics,
anti-viral drugs, therapeutics, vaccines, and prevention and
control strategies would aid in addressing this emergent virus.
Some recent therapies have shown promise in inhibiting
ZIKV infections and associated disease. These therapies include
limiting viral entry into cells, targeting the ZIKV helicase protein,
use of nucleoside analogs like 2′-C-methylated nucleosides and
7-deaza-2′-C-methyladenosine to terminate nascent RNA strand
formation, and use of antibodies that bind to ZIKV but do
not neutralize it, reducing the risk of ADE. ADE is of major
concern in the application of ZIKV therapies in geographical
regions where other flaviviruses are endemic. Thus, to limit
ADE, antibodies are being engineering to contain a modified
Fc region. Modification of the Fc region of antibodies not only
hampers their attachment to FcγRs to inhibit internalization of
the immune complex, but also reduces complement binding,
preventing ADE. In the future, several such mutations may be
identified, and humanized mAbs can be genetically engineered
to prevent ADE. Combination use of such engineered antibodies
might be evaluated for synergistic effects in other therapeutic and
prophylactic regimens.
Encouraging results with repurposed drugs, as shown by the
use of chloroquine, a malaria drug, has led to the screening
of several other FDA-approved drugs, including niclosamide,
emricasan, and daptomycin, palonosetron, kitasamycin, and
many more, for ZIKV treatment. Another valuable strategy for
the discovery of ZIKV preventives and anti-virals is the use of
computational analysis.
More insights into genetic and molecular mechanisms
associated with the recent increase in virulence of ZIKV could
aid in the design and development of safer and more potent
drugs and therapeutics against ZIKV. Along with identifying
novel drug targets, therapeutics, and vaccines, strengthening
of appropriate prevention and control measures, including
mosquito control, could help in limiting ZIKV infections, its
associated complications, and its potential for further spread. It is
time for researchers, pharmaceutical companies, policy makers,
regulators, and funding agencies to identify and implement
strategies to counter ZIKV globally.
What We Are Still Lacking
Since the declaration of the Zika epidemic as an international
public health emergency by WHO in 2016, research on ZIKV has
increased many fold. However, there are areas that still need to be
addressed.
(1) The percent contribution of each route of ZIKV infection
is not precisely understood. Presently, based on mathematical
modeling study, sexual transmission has been estimated to
account for upto 3% of transmission, but contributions by other
routes of infection are yet to be studied. This knowledge may
be helpful in designing precisely targeted inhibitory molecules to
block infection at site of entry.
(2) Many FDA approved drugs have been tested for efficacy
against ZIKV; which can be repurposed for treating ZIKV
infection in human. However, to date, no FDA category A drug
has been identified clinically safe for use in mothers and fetuses.
(3) For engineered mAb, only two mutations that prevent
internalization of immune complexes, i.e., LALA and N297A
substitutions, have been identified. More such mutations must be
identified for optimal efficacy and synergism.
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